Recently, the therapy for individuals with NSCLC using inhibitors targeting immune checkpoint pathways, including PD‐1 (such as nivolumab) and PDL‐1 (including atezolizumab, durvalumab, avelumab), has shown enhanced clinical outcomes [158]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.